These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Novel drug combinations for the management of relapsed/refractory multiple myeloma. Usmani SZ; Lonial S Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S71-7. PubMed ID: 25486960 [TBL] [Abstract][Full Text] [Related]
4. [Development of novel agents for multiple myeloma; now and the future]. Hata H Rinsho Ketsueki; 2011 Aug; 52(8):603-8. PubMed ID: 21897065 [No Abstract] [Full Text] [Related]
5. [Present status and perspective of targeted therapy for B-cell lymphoma]. Ohmachi K Rinsho Ketsueki; 2011 Aug; 52(8):609-17. PubMed ID: 21897066 [No Abstract] [Full Text] [Related]
6. [New drugs in the treatment of multiple myeloma]. Oriol A; Motlló C Med Clin (Barc); 2014 Sep; 143(6):268-74. PubMed ID: 24342015 [TBL] [Abstract][Full Text] [Related]
10. The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide. Schmitt S; Ho AD; Goldschmidt H Onkologie; 2010; 33(4):183-6. PubMed ID: 20389145 [TBL] [Abstract][Full Text] [Related]
11. Current therapeutic strategy for multiple myeloma. Suzuki K Jpn J Clin Oncol; 2013 Feb; 43(2):116-24. PubMed ID: 23293370 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation]. Tsurumi H Rinsho Ketsueki; 2014 Oct; 55(10):2027-35. PubMed ID: 25297768 [No Abstract] [Full Text] [Related]
13. Safety issues and management of toxicities associated with new treatments for multiple myeloma. Brioli A; Mügge LO; Hochhaus A; Von Lilienfeld-Toal M Expert Rev Hematol; 2017 Mar; 10(3):193-205. PubMed ID: 28116920 [TBL] [Abstract][Full Text] [Related]
14. FDA approves new agent for multiple myeloma. Fenichel MP J Natl Cancer Inst; 2015 Jun; 107(6):djv165. PubMed ID: 26032612 [No Abstract] [Full Text] [Related]
15. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma. Laubach JP; Paba Prada CE; Richardson PG; Longo DL Clin Pharmacol Ther; 2017 Jan; 101(1):81-88. PubMed ID: 27806428 [TBL] [Abstract][Full Text] [Related]
16. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies. Morgan G Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634 [TBL] [Abstract][Full Text] [Related]
17. Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Catley L; Tai YT; Chauhan D; Anderson KC Drug Resist Updat; 2005 Aug; 8(4):205-18. PubMed ID: 16019253 [TBL] [Abstract][Full Text] [Related]